ask why
Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

New medicines: EU opinions and licences, US approvals

CHMP opinions and European Commission licences from the European Medicines Agency, and new medicines approved by the US FDA. Shown in the regulator's own words, with a link to the source; checked every two hours. This is regulatory news, not medical advice, and not sponsored.

November 2026

US · FDA approval, new medicine

Neladalkib (Nelkarmi)

To treat locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer after certain previous therapies

Approved 17 Nov 2026
US · FDA approval, new medicine

Giredestrant (Wilserdly)

To treat adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor 1-mutated locally advanced or metastatic breast cancer whose disease has recurred during or after endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

In ER+/HER2− advanced breast cancer after a CDK4/6 inhibitor, giredestrant plus everolimus improved PFS vs standard endocrine therapy plus everolimus: median 10.0 vs 5.5 months in ESR1-mutated (HR 0.38) and 8.8 vs 5.5 overall (HR 0.56); adverse events similar. RCT · phase 3 · n = 373 · N Engl J Med · 2026

1 trial is being summarised and will appear here shortly.

Approved 16 Nov 2026
US · FDA approval, new medicine

Gefurulimab-gaks (Klygefa)

To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

In 260 adults with AChR antibody-positive generalised myasthenia gravis, weekly subcutaneous gefurulimab improved MG-ADL score at 26 weeks vs placebo (−4.2 vs −2.6; difference −1.6, P<.001); QMG also improved; adverse events were similar. RCT · phase 3 · n = 260 · JAMA Neurol · 2026

Approved 13 Nov 2026
US · FDA approval, new medicine

Pimicotinib (Pimjetmi)

To treat adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

In 94 adults with unresectable, symptomatic tenosynovial giant cell tumour, pimicotinib gave a week-25 objective response rate of 54% vs 3% with placebo (difference 51%). Grade 3–4 creatine phosphokinase rise occurred in 13%; mostly mild adverse events. RCT · phase 3 · n = 94 · Lancet · 2026

Approved 13 Nov 2026
EU · CHMP positive opinion

Aumolertinib (Aumseqa)

Treatment of non-small cell lung cancer in adults.

CHMP opinion 12 Nov 2026 · SFL Pharmaceuticals Deutschland GmbH
EU · CHMP positive opinion

Baxdrostat (Baxfendy)

Treatment of hypertension in adults.

CHMP opinion 12 Nov 2026 · AstraZeneca AB
EU · CHMP positive opinion: new indication

Dolutegravir;lamivudine (Dovato)

New indication (HIV Infections). The wording is on the EMA page.

CHMP opinion 12 Nov 2026 · ViiV Healthcare B.V.
EU · CHMP positive opinion: new indication

Ertugliflozin (Steglatro)

New indication (Diabetes Mellitus, Type 2). The wording is on the EMA page.

CHMP opinion 12 Nov 2026 · Merck Sharp & Dohme B.V.
EU · CHMP positive opinion

Fondaparinux sodium (Fondaparinux sodium Evumed)

Prevention of venous thromboembolic events (VTE), treatment of deep vein thrombosis (DVT), treatment of pulmonary embolism, treatment of unstable angina and myocardial infarction in adults

Generic
CHMP opinion 12 Nov 2026 · Evumed Limited
EU · EU licence (European Commission)

Glepaglutide (Zeydovio)

Zeydovio is indicated for the treatment of adults with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.

CHMP opinion 17 Sept 2026 → EU licence 12 Nov 2026 · Zealand Pharma A/S
EU · CHMP positive opinion

Insulin aspart (Donrafylix)

Treatment of diabetes mellitus from 1 year of age.

Biosimilar
CHMP opinion 12 Nov 2026 · Kuraci
EU · CHMP positive opinion

Insulin aspart (Garzulys)

Treatment of diabetes mellitus from 1 year of age.

Biosimilar
CHMP opinion 12 Nov 2026 · Sciencepharma Sp. z o.o
EU · CHMP positive opinion: new indication

Meningococcal group B Vaccine (rDNA, component, adsorbed) (Bexsero)

New indication (Meningitis, Meningococcal). The wording is on the EMA page.

CHMP opinion 12 Nov 2026 · GSK Vaccines S.r.l.
EU · CHMP positive opinion: new indication

Obinutuzumab (Gazyvaro)

Gazyvaro is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active, autoantibody-positive systemic lupus erythematosus (SLE) despite standard therapy.

CHMP opinion 12 Nov 2026 · Roche Registration GmbH
EU · CHMP positive opinion: new indication

Osilodrostat (Isturisa)

New indication (Cushing Syndrome). The wording is on the EMA page.

Orphan
CHMP opinion 12 Nov 2026 · Recordati Rare Diseases
EU · EU licence (European Commission)

Povorcitinib (Povofortay)

Povofortay is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults who have responded inadequately to, or who are intolerant or contraindicated to an anti-TNF therapy.

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

In two identical phase 3 trials of 1,227 adults with moderate to severe hidradenitis suppurativa, oral povorcitinib 45 or 75 mg raised week-12 HiSCR50 vs placebo (40–42% vs 30% and 29%). Serious adverse events: 5–6% by week 54; acne was common (17–20%). RCT · phase 3 · n = 1,227 · Nat Med · 2026

CHMP opinion 17 Sept 2026 → EU licence 12 Nov 2026 · Incyte Biosciences Distribution B.V.
EU · EU licence (European Commission)

Ruxolitinib (Ruxolitinib Zentiva)

Myelofibrosis (MF) Ruxolitinib Zentiva is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. Polycythaemia vera (PV) Ruxolitinib… Show the full indication

Myelofibrosis (MF) Ruxolitinib Zentiva is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. Polycythaemia vera (PV) Ruxolitinib Zentiva is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. Graft versus host disease (GvHD) &nbsp;Acute GvHD Ruxolitinib Zentiva is indicated for the treatment of adults and paediatric patients aged 28 days and older with acute graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1). Chronic GvHD Ruxolitinib Zentiva is indicated for the treatment of adults and paediatric patients aged 6 months and older with chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1).

Generic
CHMP opinion 17 Sept 2026 → EU licence 12 Nov 2026 · Zentiva k.s.
EU · CHMP positive opinion

Ruxolitinib (Ruxolitinib Krka)

Treatment of myelofibrosis (MF) and polycythaemia vera (PV) in adults, and treatment of Graft versus host disease (GvHD) in adults and children.

Generic
CHMP opinion 12 Nov 2026 · KRKA tovarna zdravil d.d. Novo mesto
EU · CHMP positive opinion: new indication

Secukinumab (Cosentyx)

Adolescent hidradenitis suppurativa (HS) Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adolescents 12 years and older with an inadequate response to conventional systemic HS therapy (see section 5.1).

CHMP opinion 12 Nov 2026 · Novartis Europharm Limited
EU · CHMP positive opinion

Sintilimab (Zybrivo)

Treatment of non-squamous non-small cell lung cancer in adults.

CHMP opinion 12 Nov 2026 · Fortvita Biologics (Ireland) Limited
EU · EU licence (European Commission)

Tofacitinib (Inijaq)

Rheumatoid arthritis&nbsp; Tofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).&nbsp; Tofacitinib can be given as… Show the full indication

Rheumatoid arthritis&nbsp; Tofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).&nbsp; Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.&nbsp;&nbsp; Psoriatic arthritis&nbsp; Tofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.&nbsp;&nbsp; Ankylosing spondylitis&nbsp; Tofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.&nbsp;&nbsp; Ulcerative colitis&nbsp; Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.&nbsp;&nbsp; Juvenile idiopathic arthritis (JIA)&nbsp; Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with DMARDs.&nbsp; Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.

Generic
CHMP opinion 17 Sept 2026 → EU licence 12 Nov 2026 · Gedeon Richter Plc.
US · FDA approval, new medicine

Asundexian (Sunharbo)

To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack

Approved 9 Nov 2026

October 2026

EU · EU licence (European Commission)

Linerixibat (Lynavoy)

Lynavoy is indicated for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC).

Orphan
CHMP opinion 23 Jul 2026 → EU licence 22 Oct 2026 · GlaxoSmithKline Trading Services Limited
US · FDA approval, new medicine

Bepirovirsen (Hibsago)

To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy

Approved 20 Oct 2026
EU · CHMP positive opinion

Daraxonrasib (Rasonque)

Treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.

Orphan
CHMP opinion 15 Oct 2026 · Revolution Medicines Netherlands B.V.
EU · CHMP negative opinion

Narsoplimab (Yartemlea)

Treatment of patients with haemopoietic stem cell transplant-associated thrombotic microangiopathy&nbsp;

Negative
CHMP opinion 15 Oct 2026 · Omeros Ireland Limited
EU · CHMP positive opinion

Orforglipron (Foundayo)

Treatment of obesity and type 2 diabetes mellitus in adults

CHMP opinion 15 Oct 2026 · Eli Lilly Nederland B.V.
EU · CHMP positive opinion

Filgrastim (Neuzafy)

Treatment of neutropenia in adults and children

Biosimilar
CHMP opinion 15 Oct 2026 · CuraTeQ Biologics (Malta) Limited
EU · CHMP positive opinion: new indication

Insulin icodec;semaglutide (Kyinsu)

New indication (Diabetes Mellitus, Type 2). The wording is on the EMA page.

CHMP opinion 15 Oct 2026 · Novo Nordisk A/S
EU · CHMP positive opinion: new indication

Pandemic influenza vaccine (H5N1) (live attenuated, nasal) (Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune))

New indication (Influenza, Human). The wording is on the EMA page.

Conditional
CHMP opinion 15 Oct 2026 · AstraZeneca AB
EU · CHMP positive opinion: new indication

Talquetamab (Talvey)

Talvey is indicated: in combination with daratumumab and pomalidomide or in combination with daratumumab, for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least one prior therapy. as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who… Show the full indication

Talvey is indicated: in combination with daratumumab and pomalidomide or in combination with daratumumab, for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least one prior therapy. as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti CD38 antibody and have demonstrated disease progression on the last therapy. Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission. Note: New text in bold CHMP post-authorisation summary of positive opinion for Talvey (VR-0000339914) Adopted Reference Number: EMADOC-1700519818-3395421 English (EN) (123.5 KB - PDF) First published: 16/10/2026 View Key facts Name of medicine Talvey EMA product number EMEA/H/C/005864 Active substance talquetamab International non-proprietary name (INN) or common name talquetamab Therapeutic area (MeSH) Multiple Myeloma Anatomical therapeutical chemical (ATC) code L01FX29 Additional monitoring This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicin

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

Interim analysis, phase 3, 864 patients with relapsed/refractory myeloma: talquetamab-daratumumab-pomalidomide and talquetamab-daratumumab both prolonged PFS vs daratumumab-pomalidomide-dexamethasone (HR 0.28 and 0.33). Serious adverse events 63.0%, 52.6%, 53.7%. RCT · phase 3 · n = 864 · N Engl J Med · 2026

ConditionalPRIME
CHMP opinion 15 Oct 2026 · Janssen-Cilag International N.V.
EU · CHMP positive opinion

Temozolomide (Kizfizo)

Treatment of adults with glioblastoma multiforme and children with malignant glioma&nbsp;

Orphan
CHMP opinion 15 Oct 2026 · ORPHELIA Pharma
EU · CHMP positive opinion: new indication

Tucatinib (Tukysa)

HER2-positive breast cancer Tukysa is indicated in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable or metastatic HER2-positive breast cancer following first-line chemotherapy.

CHMP opinion 15 Oct 2026 · Pfizer Europe MA EEIG
US · FDA approval, new medicine

Pritelivir (Hovilpri)

To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies

Approved 9 Oct 2026

September 2026

EU · EU licence (European Commission)

Pegfilgrastim (Cavoley)

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Biosimilar
CHMP opinion 23 Jul 2026 → EU licence 25 Sept 2026 · CuraTeQ Biologics s.r.o
US · FDA approval, new medicine

Tavapadon (Juvmo)

To treat Parkinson’s disease in adults

Approved 25 Sept 2026
US · FDA approval, new medicine

Zilurgisertib (Atebrioz)

To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva

Approved 25 Sept 2026
US · FDA approval, new medicine

Insulin efsitora alfa-gobe (Onswik)

To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

2 trials are being summarised and will appear here shortly.

Approved 23 Sept 2026
US · FDA approval, new medicine

Lirafugratinib (Lyrfigtu)

To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement

Approved 23 Sept 2026
EU · EU licence (European Commission)

Leriglitazone (Nezglyal)

Nezglyal is indicated for the treatment of Cerebral Adrenoleukodystrophy (cALD) in males with Adrenoleukodystrophy (ALD) aged 2 to 12 years with non Gadolinium (Gd) enhancing lesions (i.e. Gd negative) in brain Magnetic Resonance Imaging (MRI), with a Neurological Functional Score (NFS) of 0 or 1.

OrphanExceptional circumstances
CHMP opinion 23 Jul 2026 → EU licence 21 Sept 2026 · Minoryx Therapeutics S.L.
EU · EU licence (European Commission)

Ensitrelvir (Zokovea)

Post exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

2 trials are being summarised and will appear here shortly.

CHMP opinion 23 Jun 2026 → EU licence 18 Sept 2026 · Shionogi B.V.
EU · EU licence (European Commission)

Icotrokinra hydrochloride (Icotyde)

Icotyde is indicated for the treatment of moderate to severe plaque psoriasis in adults, and adolescents 12&nbsp;years of age and older and weighing at least 40&nbsp;kg, who are candidates for systemic therapy

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

2 trials are being summarised and will appear here shortly.

CHMP opinion 23 Jul 2026 → EU licence 18 Sept 2026 · Janssen-Cilag International
EU · EU licence (European Commission)

Ranibizumab (Susvimo)

Susvimo is indicated in adult patients for the treatment of neovascular (wet) age-related macular degeneration (nAMD) who have achieved stable disease after previously responding to intravitreal treatment with a vascular endothelial growth factor (VEGF) inhibitor medicinal product.

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

2 trials are being summarised and will appear here shortly.

CHMP opinion 23 Jul 2026 → EU licence 18 Sept 2026 · Roche Registration GmbH
EU · EU licence (European Commission)

Ruxolitinib hemifumarate (Ruxolitinib Viatris)

Myelofibrosis (MF)&nbsp; Ruxolitinib Viatris is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.&nbsp; Polycythaemia vera (PV)&nbsp;… Show the full indication

Myelofibrosis (MF)&nbsp; Ruxolitinib Viatris is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.&nbsp; Polycythaemia vera (PV)&nbsp; Ruxolitinib Viatris is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.&nbsp; Graft versus host disease (GvHD)&nbsp;&nbsp; Acute GvHD&nbsp;Ruxolitinib Viatris is indicated for the treatment of adults and paediatric patients aged 28 days and older with acute graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1). Chronic GvHD&nbsp;Ruxolitinib Viatris is indicated for the treatment of adults and paediatric patients aged 6 months and older with chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1).

Generic
CHMP opinion 23 Jul 2026 → EU licence 18 Sept 2026 · Viatris Limited
EU · EU licence (European Commission)

Tafamidis (Tafamidis Accord)

Tafamidis Accord is indicated for the treatment of hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTRh-CM).

Generic
CHMP opinion 23 Jul 2026 → EU licence 18 Sept 2026 · Accord Healthcare S.L.U.
EU · CHMP negative opinion

Allogeneic faecal microbiota, pooled (Xervyteg)

Treatment of adult patients with acute-graft-versus-host disease (aGvHD)&nbsp;

Negative
CHMP opinion 17 Sept 2026 · MaaT PHARMA
EU · CHMP positive opinion: new indication

Dabigatran etexilate (Pradaxa)

New indication (Arthroplasty, Replacement, Venous Thromboembolism). The wording is on the EMA page.

CHMP opinion 17 Sept 2026 · Boehringer Ingelheim International GmbH
EU · CHMP positive opinion

Denecimig (Frehemgo)

Prophylaxis of bleeding episodes in patients with haemophilia A

CHMP opinion 17 Sept 2026 · Novo Nordisk A/S
EU · CHMP positive opinion

Ensartinib (Gevalka)

The treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

In 274 patients with resected ALK-positive stage IB–IIIB NSCLC after adjuvant chemotherapy, 24 months of ensartinib vs placebo raised 24-month disease-free survival in stage II–IIIB disease (86.4% vs 53.5%; HR 0.20). Grade ≥3 adverse events: 35.8% vs 18.2%. RCT · phase 3 · n = 274 · N Engl J Med · 2026

1 trial is being summarised and will appear here shortly.

CHMP opinion 17 Sept 2026 · SFL Pharmaceuticals Deutschland GmbH
EU · CHMP positive opinion

Gefurulimab (Klygefa)

Treatment of adult patients with generalised myasthemia gravis (gMG)

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

In 260 adults with AChR antibody-positive generalised myasthenia gravis, weekly subcutaneous gefurulimab improved MG-ADL score at 26 weeks vs placebo (−4.2 vs −2.6; difference −1.6, P<.001); QMG also improved; adverse events were similar. RCT · phase 3 · n = 260 · JAMA Neurol · 2026

CHMP opinion 17 Sept 2026 · Alexion Europe
EU · CHMP positive opinion: new indication

Melphalan flufenamide (Pepaxti)

New indication (Multiple Myeloma). The wording is on the EMA page.

CHMP opinion 17 Sept 2026 · Oncopeptides AB (publ)
EU · CHMP positive opinion

Rabies vaccine (inactivated) for human (VaxRabeo)

Pre-exposure and post-exposure prophylaxis against rabies in all age groups

CHMP opinion 17 Sept 2026 · Sanofi Winthrop Industrie
EU · CHMP positive opinion

Relacorilant (Lifyorli)

Treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

2 trials are being summarised and will appear here shortly.

Orphan
CHMP opinion 17 Sept 2026 · Corcept Therapeutics Netherlands B.V.
EU · CHMP positive opinion

Senaparib (Sepalna)

Maintenance treatment of advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

1 trial is being summarised and will appear here shortly.

CHMP opinion 17 Sept 2026
EU · CHMP positive opinion: new indication

Somapacitan (Sogroya)

New indication (Growth). The wording is on the EMA page.

CHMP opinion 17 Sept 2026 · Novo Nordisk A/S
EU · CHMP positive opinion: new indication

Trastuzumab deruxtecan (Enhertu)

Early breast cancer Enhertu as monotherapy is indicated for the adjuvant treatment of adult patients with resected HER2-positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2-targeted treatment (for biomarker-based patient selection, see section 4.2).

Conditional
CHMP opinion 17 Sept 2026 · Daiichi Sankyo Europe GmbH
US · FDA approval, new medicine

Apitegromab-mstn (Isembyld)

To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment

Approved 11 Sept 2026
US · FDA approval, new medicine

Floretyrosine F 18 (Pixclara)

To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations

Approved 11 Sept 2026
US · FDA approval, new medicine

Camizestrant (Etcamah)

To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy

Approved 4 Sept 2026

August 2026

EU · EU licence (European Commission)

Denosumab (Denosumab Ascend)

Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.&nbsp;

Biosimilar
CHMP opinion 25 Jun 2026 → EU licence 28 Aug 2026 · Ascend GmbH
EU · EU licence (European Commission)

Influenza vaccine (surface antigen, inactivated, adjuvanted, prepared in cell culture) (Aujemflu)

Prophylaxis of influenza in adults 50 years of age and older. Aujemflu should be used in accordance with official recommendations.

CHMP opinion 25 Jun 2026 → EU licence 20 Aug 2026 · Seqirus Netherlands B.V.
EU · EU licence (European Commission)

Levodopa;carbidopa (Hopledo)

Hopledo is indicated for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilised with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens.

CHMP opinion 25 Jun 2026 → EU licence 20 Aug 2026 · Zambon SpA
EU · EU licence (European Commission)

Trofinetide (Daybu)

Daybu is indicated for the treatment of neurobehavioural symptoms of Rett syndrome in adults and paediatric patients aged 5 years and older.&nbsp;

Orphan
CHMP opinion 25 Jun 2026 → EU licence 20 Aug 2026 · Acadia Pharmaceuticals B.V.
US · FDA approval, new medicine

Garetosmab-grts (Pasatru)

To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva

Approved 19 Aug 2026
US · FDA approval, new medicine

Florquinitau F 18 (Tauklarify)

To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology

Approved 13 Aug 2026
US · FDA approval, new medicine

Iberdomide (Zenbexus)

To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent

Approved 13 Aug 2026

July 2026

EU · EU licence (European Commission)

Colchicine (Colchicine Agepha Pharma)

Colchicine AGEPHA Pharma is indicated for secondary prevention of atherothrombotic events in adult patients with coronary disease stable for at least 6 months.

CHMP opinion 21 May 2026 → EU licence 24 Jul 2026 · Agepha Pharma s.r.o.
EU · CHMP negative opinion

Arimoclomol (Meplyffa)

Treatment of Niemann-Pick disease type C (NPC) in patients aged 6 months and older in combination with miglustat.

NegativeOrphan
CHMP opinion 23 Jul 2026 · Zevra Denmark A/S
EU · CHMP negative opinion

Catequentinib (Qezzaqar)

Treatment of synovial sarcoma or leiomyosarcoma.

NegativeOrphan
CHMP opinion 23 Jul 2026 · CATS Consultants GmbH
EU · CHMP positive opinion: new indication

Formoterol fumarate dihydrate;glycopyrronium;budesonide (Riltrava Aerosphere)

New indication (Pulmonary Disease, Chronic Obstructive). The wording is on the EMA page.

CHMP opinion 23 Jul 2026 · AstraZeneca AB
EU · CHMP positive opinion

Lerodalcibep (Lyrokaul)

It is indicated in adults with primary hypercholesterolaemia (heterozygous familial (HeFH) and non-familial) or mixed dyslipidaemia as an adjunct to diet.

CHMP opinion 23 Jul 2026 · LIB Therapeutics B.V.
EU · CHMP positive opinion

Obicetrapib;ezetimibe (Evlarco)

Treatment of primary hypercholesterolaemia or mixed dyslipidaemia.

CHMP opinion 23 Jul 2026 · A. Menarini International Licensing S.A.
EU · CHMP positive opinion

Riociguat (Riociguat Accord)

Treatment of Chronic thromboembolic pulmonary hypertension (CTEPH) in adults and treatment of Pulmonary arterial hypertension (PAH) in adults and children from 6 years of age.

Generic
CHMP opinion 23 Jul 2026 · Accord Healthcare S.L.U.
EU · CHMP negative opinion

Sufentanil;ketamine (KemSu)

Treatment of acute pain in children aged 1 to less than 18 years.

Negative
CHMP opinion 23 Jul 2026 · Proveca Pharma Limited
US · FDA approval, new medicine

Zidesamtinib (Jideytro)

To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor

Approved 22 Jul 2026
EU · EU licence (European Commission)

Camizestrant (Etcamah)

Etcamah&nbsp;in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of&nbsp;adult&nbsp;patients with ER-positive,&nbsp;HER2-negative,&nbsp;locally advanced or metastatic breast&nbsp;cancer upon detection of ESR1‑mutation and without disease progression during first-line endocrine… Show the full indication

Etcamah&nbsp;in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of&nbsp;adult&nbsp;patients with ER-positive,&nbsp;HER2-negative,&nbsp;locally advanced or metastatic breast&nbsp;cancer upon detection of ESR1‑mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor (for biomarker based patient-selection, see section 4.2 and 5.1).

CHMP opinion 21 May 2026 → EU licence 20 Jul 2026 · AstraZeneca AB
EU · EU licence (European Commission)

Alpelisib (Vijoice)

Treatment of adult and paediatric patients aged 2 years and older with severe or life-threatening manifestations of PIK3CA-related overgrowth spectrum (PROS)

OrphanConditional
CHMP opinion 21 May 2026 → EU licence 15 Jul 2026 · Novartis Europharm Limited
EU · EU licence (European Commission)

Liraglutide (Liraglutide STADA)

Treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise

CHMP opinion 21 May 2026 → EU licence 15 Jul 2026 · STADA Arzneimittel AG
EU · EU licence (European Commission)

Nerandomilast (Jascayd)

Jascayd is indicated for the treatment of adult patients with Idiopathic Pulmonary Fibrosis (IPF). Jascayd is indicated for the treatment of adult patients with Progressive Pulmonary Fibrosis (PPF).

CHMP opinion 21 May 2026 → EU licence 15 Jul 2026 · Boehringer Ingelheim International GmbH
EU · EU licence (European Commission)

Ranibizumab (Vislyfa)

Vislyfa is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion… Show the full indication

Vislyfa is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) The treatment of visual impairment due to choroidal neovascularisation (CNV)

Biosimilar
CHMP opinion 21 May 2026 → EU licence 15 Jul 2026 · Lupin Europe GmbH
EU · EU licence (European Commission)

TrenibotulinumtoxinE (Boey)

Boey is indicated for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frown (glabellar lines), when these have an important psychological impact in adult patients.

CHMP opinion 21 May 2026 → EU licence 15 Jul 2026 · AbbVie Limited
US · FDA approval, new medicine

Gedatolisib (Revtorpyk)

In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting

Approved 14 Jul 2026
US · FDA approval, new medicine

Atacicept-vymj (Trutakna)

To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression

Approved 7 Jul 2026

June 2026

EU · EU licence (European Commission)

Onasemnogene abeparvovec (Itvisma)

Itvisma is indicated for the treatment of 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene in patients 2 years of age and older.

CHMP opinion 23 Apr 2026 → EU licence 30 Jun 2026 · Novartis Europharm Limited
EU · CHMP negative opinion

Autologous melanoma-derived tumor infiltrating lymphocytes, ex vivo-expanded (Tacquell)

Tacquell is indicated for the treatment of adult patients with unresectable stage IIIC to IV melanoma following prior anti-Programmed Death-1 (PD-1)-based checkpoint inhibitor treatment given either as first line treatment for unresectable stage III or IV disease, or given as (neo)adjuvant therapy.&nbsp;

Negative
CHMP opinion 25 Jun 2026 · Netherlands Cancer Institute
EU · CHMP positive opinion

Insulin efsitora alfa (Onswik)

Treatment of type 2 diabetes mellitus&nbsp;

CHMP opinion 25 Jun 2026 · Eli Lilly Nederland B.V.
EU · CHMP positive opinion

Pegfilgrastim (Nylaspeg)

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).&nbsp;

Biosimilar
CHMP opinion 25 Jun 2026 · Qilu Pharma Spain S.L.
EU · EU licence (European Commission)

Palbociclib (Palbociclib Viatris)

Palbociclib Viatris is indicated for the treatment of hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer. in combination with an aromatase inhibitor; in combination with fulvestrant in women who have received prior endocrine therapy (see section&nbsp;5.1).… Show the full indication

Palbociclib Viatris is indicated for the treatment of hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer. in combination with an aromatase inhibitor; in combination with fulvestrant in women who have received prior endocrine therapy (see section&nbsp;5.1). In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone‑releasing hormone (LHRH) agonist.

Generic
CHMP opinion 23 Apr 2026 → EU licence 19 Jun 2026 · Viatris Limited
EU · EU licence (European Commission)

Plozasiran (Redemplo)

Redemplo is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) (see section 4.2 for patient selection criteria).

Orphan
CHMP opinion 23 Apr 2026 → EU licence 19 Jun 2026 · Arrowhead Pharmaceuticals Ireland Limited
EU · EU licence (European Commission)

Ranibizumab (Rexatilux)

Rexatilux is indicated in adults for: - The treatment of neovascular (wet) age-related macular degeneration (AMD) - The treatment of visual impairment due to diabetic macular oedema (DME) - The treatment of proliferative diabetic retinopathy (PDR) - The treatment of visual impairment due to macular oedema secondary to retinal vein… Show the full indication

Rexatilux is indicated in adults for: - The treatment of neovascular (wet) age-related macular degeneration (AMD) - The treatment of visual impairment due to diabetic macular oedema (DME) - The treatment of proliferative diabetic retinopathy (PDR) - The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) - The treatment of visual impairment due to choroidal neovascularisation (CNV).

Biosimilar
CHMP opinion 23 Apr 2026 → EU licence 19 Jun 2026 · Intas Third Party Sales 2005 S.L.
EU · EU licence (European Commission)

Tolebrutinib (Cenrifki)

Cenrifki is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) without relapses in the last 2 years.

CHMP opinion 23 Apr 2026 → EU licence 19 Jun 2026 · Sanofi Winthrop Industrie
US · FDA approval, new medicine

Tebipenem pivoxil (Utebzi)

To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options

Approved 17 Jun 2026
US · FDA approval, new medicine

Gadoquatrane (Ambelvist)

To detect and visualize lesions with abnormal vascularity, in conjunction with MRI

Approved 12 Jun 2026

May 2026

EU · EU licence (European Commission)

Furosemide (Bopediat)

Bopediat is indicated in children from birth to less than 18 years of age for the treatment of oedema of cardiac or renal origin, oedema of hepatic origin, and hypertension in patients with chronic kidney disease.

CHMP opinion 26 Mar 2026 → EU licence 29 May 2026 · Proveca Pharma Limited
EU · EU licence (European Commission)

Lurbinectedin (Zepzelca)

Zepzelca, in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.

Orphan
CHMP opinion 26 Mar 2026 → EU licence 29 May 2026 · Pharma Mar S.A.
EU · EU licence (European Commission)

Tarlatamab (Imdylltra)

Imdylltra is indicated as monotherapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy.

Orphan
CHMP opinion 26 Mar 2026 → EU licence 29 May 2026 · Amgen Europe B.V.
US · FDA approval, new medicine

Cefepime and zidebactam (Zaynich)

To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms

Approved 29 May 2026
EU · EU licence (European Commission)

Nadofaragene firadenovec (Adstiladrin)

Adstiladrin is indicated as monotherapy for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.

ConditionalAdvanced therapy
CHMP opinion 26 Mar 2026 → EU licence 28 May 2026 · Ferring Pharmaceuticals A/S
EU · CHMP negative opinion

Copper (64Cu) oxodotreotide (Deqtynet)

Positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine neoplasms (NENs).

NegativeOrphan
CHMP opinion 21 May 2026 · CIS bio international
EU · EU licence (European Commission)

Leniolisib (Joenja)

Joenja is indicated for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older and weighing 45 kg or more.

OrphanExceptional circumstances
CHMP opinion 26 Mar 2026 → EU licence 21 May 2026 · Pharming Technologies B.V.
EU · CHMP positive opinion: new indication

Pegvaliase (Palynziq)

New indication (Phenylketonurias). The wording is on the EMA page.

Orphan
CHMP opinion 21 May 2026 · BioMarin International Limited
US · FDA approval, new medicine

Sonrotoclax (Beqalzi)

To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor

Approved 13 May 2026
EU · EU licence (European Commission)

Insulin lispro (Bysumlog)

For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Bysumlog is also indicated for the initial stabilisation of diabetes mellitus.

Biosimilar
CHMP opinion 26 Feb 2026 → EU licence 6 May 2026 · Sandoz GmbH
US · FDA approval, new medicine

Vepdegestrant (Veppanu)

To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

Approved 1 May 2026

April 2026

EU · EU licence (European Commission)

Insulin aspart (Dazparda)

Dazparda is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Biosimilar
CHMP opinion 26 Feb 2026 → EU licence 27 Apr 2026 · Sandoz GmbH
EU · EU licence (European Commission)

Levodopa;carbidopa (Onerji)

Onerji is indicated for the treatment of motor fluctuations in patients with advanced Parkinson's disease which are not sufficiently controlled by oral anti-Parkinson medicinal products.

CHMP opinion 26 Feb 2026 → EU licence 27 Apr 2026 · Tanabe Pharma GmbH
EU · EU licence (European Commission)

Mavorixafor (Xolremdi)

Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.

OrphanExceptional circumstances
CHMP opinion 26 Feb 2026 → EU licence 27 Apr 2026 · Norgine B.V.
EU · EU licence (European Commission)

Teriparatide (Zandoriah)

Teriparatide is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained… Show the full indication

Teriparatide is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

Biosimilar
CHMP opinion 26 Feb 2026 → EU licence 27 Apr 2026 · CinnaGen Co Unipessoal LDA
EU · EU licence (European Commission)

Tocilizumab (Tuyory)

Rheumatoid arthritis (RA) Tuyory, in combination with methotrexate (MTX), is indicated for:- the treatment of severe, active and progressive RA in adults not previously treated with MTX.- the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy… Show the full indication

Rheumatoid arthritis (RA) Tuyory, in combination with methotrexate (MTX), is indicated for:- the treatment of severe, active and progressive RA in adults not previously treated with MTX.- the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease- modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, Tuyory can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Tocilizumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate. Coronavirus disease 2019 (COVID-19) Tuyory is indicated for the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. Systemic juvenile idiopathic arthritis (sJIA) Tuyory is indicated for the treatment of active sJIA in patients 1 year of age and older, who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Tuyory can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.Polyarticular juvenile idiopathic arthritis (pJIA) Tuyory in combination with MTX is indicated for the treatment of pJIA (rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. Tuyory can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Cytokine release syndrome (CRS) Tuyory is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening CRS in adults and paediatric patients 2 years of age and older. Giant cell arteritis (GCA) Tuyory is indicated for the treatment of GCA in adult patients.

Biosimilar
CHMP opinion 26 Feb 2026 → EU licence 27 Apr 2026 · Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)
EU · CHMP positive opinion: new indication

Burosumab (Crysvita)

New indication (Hypophosphatemia, Familial, Hypophosphatemic Rickets, X-Linked Dominant, Osteomalacia). The wording is on the EMA page.

Orphan
CHMP opinion 23 Apr 2026 · Kyowa Kirin Holdings B.V.
EU · EU licence (European Commission)

Etanercept (Fubelv)

Rheumatoid arthritisFubelv in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate.Fubelv can be given as monotherapy in case of intolerance… Show the full indication

Rheumatoid arthritisFubelv in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate.Fubelv can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Fubelv is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Fubelv, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.Juvenile idiopathic arthritisTreatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Psoriatic arthritisTreatment of active and progressive psoriatic arthritis in adults when the response to previous disease- modifying antirheumatic drug therapy has been inadequate. Etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. Axial spondyloarthritisAnkylosing spondylitisTreatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Non-radiographic axial spondyloarthritisTreatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs).Plaque psoriasisTreatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA).Paediatric plaque psoriasisTreatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.

Biosimilar
CHMP opinion 26 Feb 2026 → EU licence 23 Apr 2026 · Biosimilar Collaborations Ireland Limited
EU · EU licence (European Commission)

Paltusotine (Palsonify)

Palsonify is indicated for the medical treatment of adult patients with acromegaly.

Orphan
CHMP opinion 26 Feb 2026 → EU licence 23 Apr 2026 · Crinetics Pharmaceuticals Europe GmbH
EU · EU licence (European Commission)

Pertuzumab (Poherdy)

Early breast cancerPoherdy is indicated for use in combination with trastuzumab and chemotherapy in:- the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence- the adjuvant treatment of adult patients with HER2-positive early breast cancer at… Show the full indication

Early breast cancerPoherdy is indicated for use in combination with trastuzumab and chemotherapy in:- the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence- the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrenceMetastatic breast cancerPoherdy is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

Biosimilar
CHMP opinion 26 Feb 2026 → EU licence 23 Apr 2026 · Organon N.V.
EU · EU licence (European Commission)

Remibrutinib (Rhapsido)

Rhapsido is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1 antihistamine treatment.

CHMP opinion 26 Feb 2026 → EU licence 23 Apr 2026 · Novartis Europharm Limited
EU · EU licence (European Commission)

Influenza mRNA vaccine;COVID-19 mRNA vaccine (mCombriax)

mCombriax is indicated for active immunisation for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older. The use of this vaccine should be in accordance with official recommendations.

CHMP opinion 26 Feb 2026 → EU licence 20 Apr 2026 · Moderna Biotech Spain, S.L.
EU · EU licence (European Commission)

Tovorafenib (Ojemda)

Ojemda is indicated as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies (for biomarkers-based patient selection, see section 4.2)

OrphanConditional
CHMP opinion 26 Feb 2026 → EU licence 20 Apr 2026 · Ipsen Pharma
US · FDA approval, new medicine

Doravirine and islatravir (Idvynso)

To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine

Approved 20 Apr 2026
EU · EU licence (European Commission)

Clesrovimab (Enflonsia)

Enflonsia is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.Enflonsia should be used in accordance with official recommendations.

CHMP opinion 18 Sept 2025 → EU licence 15 Apr 2026 · Merck Sharp Dohme Limited
US · FDA approval, new medicine

Orforglipron (Foundayo)

To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity

Approved 1 Apr 2026

March 2026

EU · EU licence (European Commission)

Trivalent influenza vaccine (recombinant, prepared in cell culture) (Supemtek)

Supemtek is indicated for active immunisation for the prevention of influenza disease in adults and children from 9 years of age and older.&nbsp;Supemtek should be used in accordance with official recommendations.

CHMP opinion 29 Jan 2026 → EU licence 30 Mar 2026 · Sanofi Winthrop Industrie
EU · EU licence (European Commission)

Doxecitine;doxribtimine (Kygevvi)

Kygevvi is indicated for the treatment of paediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years.

OrphanPRIMEExceptional circumstances
CHMP opinion 29 Jan 2026 → EU licence 26 Mar 2026 · UCB Pharma
EU · EU licence (European Commission)

Estetrol (Fylrevy)

Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in hysterectomised postmenopausal womenHormone replacement therapy (HRT) for oestrogen deficiency symptoms in non-hysterectomised postmenopausal women with at least 12 months since last menses.

CHMP opinion 29 Jan 2026 → EU licence 26 Mar 2026 · Gedeon Richter Plc.
EU · CHMP positive opinion: new indication

Lomitapide (Lojuxta)

New indication (Hypercholesterolemia). The wording is on the EMA page.

CHMP opinion 26 Mar 2026 · Chiesi Farmaceutici SpA
EU · EU licence (European Commission)

Lutetium (177Lu) chloride (Ilumira)

Ilumira is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177Lu) chloride.

CHMP opinion 29 Jan 2026 → EU licence 26 Mar 2026 · Shine Europe B.V.
EU · EU licence (European Commission)

Semaglutide (Kayshild)

Kayshild is indicated in conjunction with diet and exercise for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (fibrosis stages F2 to F3).

Conditional
CHMP opinion 29 Jan 2026 → EU licence 26 Mar 2026 · Novo Nordisk A/S
US · FDA approval, new medicine

Relacorilant (Lifyorli)

To treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens, at least one of which included bevacizumab

Approved 25 Mar 2026
EU · EU licence (European Commission)

Belumosudil (Rezurock)

Rezurock is indicated for the treatment of adults and paediatric patients (12 years and older with a body weight of at least 40 kg) with chronic graft-versus-host disease (cGVHD) when other treatment options provide limited clinical benefit, are not suitable, or have been exhausted.&nbsp;

OrphanConditional
CHMP opinion 29 Jan 2026 → EU licence 24 Mar 2026 · Sanofi Winthrop Industrie
US · FDA approval, new medicine

Tividenofusp alfa-eknm (Avlayah)

To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)

Approved 24 Mar 2026

February 2026

EU · CHMP negative opinion

Iloperidone (Iloperidone Vanda Pharmaceuticals)

Iloperidone is indicated for: treatment of schizophrenia in adults acute treatment of manic or mixed episodes associated with bipolar I disorder in adults

Negative
CHMP opinion 26 Feb 2026 · Vanda Pharmaceuticals Netherlands B.V.
US · FDA approval, new medicine

Pegzilarginase-nbln (Loargys)

To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction

Approved 23 Feb 2026
US · FDA approval, new medicine

Milsaperidone (Bysanti)

To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder

Approved 20 Feb 2026
EU · EU licence (European Commission)

Nogapendekin alfa inbakicept (Anktiva)

Anktiva in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.

Conditional
CHMP opinion 11 Dec 2025 → EU licence 16 Feb 2026 · Immunitybio Ireland Limited
EU · EU licence (European Commission)

COVID-19 mRNA vaccine (mNexspike)

mNEXSPIKE is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. The use of this vaccine should be in accordance with official recommendations.&nbsp;

CHMP opinion 11 Dec 2025 → EU licence 12 Feb 2026 · Moderna Biotech Spain, S.L.
EU · EU licence (European Commission)

Aficamten (Myqorzo)

Myqorzo is indicated for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.

CHMP opinion 11 Dec 2025 → EU licence 12 Feb 2026 · Cytokinetics (Ireland) Limited
EU · EU licence (European Commission)

Depemokimab (Exdensur)

Asthma&nbsp; Exdensur is indicated as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled&nbsp;despite high dose inhaled corticosteroids (ICS) plus another asthma controller (see section 5.1). Chronic… Show the full indication

Asthma&nbsp; Exdensur is indicated as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled&nbsp;despite high dose inhaled corticosteroids (ICS) plus another asthma controller (see section 5.1). Chronic rhinosinusitis with nasal polyps (CRSwNP)&nbsp; Exdensur is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.

CHMP opinion 11 Dec 2025 → EU licence 12 Feb 2026 · GlaxoSmithKline Trading Services Limited
EU · EU licence (European Commission)

Golimumab (Gotenfia)

Rheumatoid arthritis (RA) Gotenfia, in combination with methotrexate (MTX), is indicated for: the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid… Show the full indication

Rheumatoid arthritis (RA) Gotenfia, in combination with methotrexate (MTX), is indicated for: the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Golimumab, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Psoriatic arthritis (PsA) Gotenfia, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Golimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. Axial spondyloarthritis Ankylosing spondylitis (AS) Gotenfia is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Non-radiographic axial spondyloarthritis (nr-Axial SpA) Gotenfia is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). Ulcerative colitis (UC) Gotenfia is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. Paediatric ulcerative colitis (pUC) Gotenfia is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients 2 years of age and older with a body weight of at least 15 kg, who have had an inadequate response to conventional therapy, including corticosteroids and 6‑mercaptopurine (6‑MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis (pJIA) Gotenfia in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.

Biosimilar
CHMP opinion 11 Dec 2025 → EU licence 10 Feb 2026 · Stada Arzneimittel AG
EU · EU licence (European Commission)

Ranibizumab (Ranluspec)

Ranluspec is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion… Show the full indication

Ranluspec is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) The treatment of visual impairment due to choroidal neovascularisation (CNV)&nbsp;

Biosimilar
CHMP opinion 11 Dec 2025 → EU licence 10 Feb 2026 · Lupin Europe GmbH

January 2026

EU · EU licence (European Commission)

L-acetylleucine (Aqneursa)

Aqneursa is indicated for the treatment of neurological manifestations of Niemann-Pick type C (NPC) disease, in combination with miglustat, or as a monotherapy in patients where miglustat is not tolerated, in adults and children aged 6 years and older and weighing at least 20 kg.

Orphan
CHMP opinion 13 Nov 2025 → EU licence 19 Jan 2026 · Intrabio Ireland Limited
EU · EU licence (European Commission)

Donidalorsen (Dawnzera)

Dawnzera is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.

CHMP opinion 13 Nov 2025 → EU licence 19 Jan 2026 · Otsuka Pharmaceutical Netherlands B.V.
EU · EU licence (European Commission)

Etuvetidigene autotemcel (Waskyra)

Waskyra is indicated for the treatment of patients aged 6 months and older with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene for whom haematopoietic stem cell (HSC) transplantation is appropriate and no suitable human leukocyte antigen (HLA)-matched related haematopoietic stem cell donor is available.

OrphanAdvanced therapy
CHMP opinion 13 Nov 2025 → EU licence 9 Jan 2026 · Fondazione Telethon ETS
EU · EU licence (European Commission)

Imlunestrant (Inluriyo)

Inluriyo is indicated as monotherapy for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1-mutation, who have disease progression following prior treatment with an endocrine based regimen (for biomarker-based patient selection, see… Show the full indication

Inluriyo is indicated as monotherapy for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1-mutation, who have disease progression following prior treatment with an endocrine based regimen (for biomarker-based patient selection, see section 4.2).In pre- or perimenopausal women, or men, Inluriyo should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

CHMP opinion 13 Nov 2025 → EU licence 9 Jan 2026 · Eli Lilly Nederland B.V.
EU · EU licence (European Commission)

Pertussis vaccine (recombinant, acellular, component, adsorbed) (VacPertagen)

VacPertagen is indicated for:&nbsp;- booster immunisation against pertussis of individuals 12 years of age and older,- passive protection against pertussis in early infancy following maternal immunisation during pregnancy.

CHMP opinion 13 Nov 2025 → EU licence 9 Jan 2026 · BioNet Europe
EU · EU licence (European Commission)

Denosumab (Osqay)

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women denosumab significantly reduces the risk of vertebral, non-vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with… Show the full indication

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women denosumab significantly reduces the risk of vertebral, non-vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, denosumab significantly reduces the risk of vertebral fractures.Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.

Biosimilar
CHMP opinion 13 Nov 2025 → EU licence 8 Jan 2026 · Theramex Ireland Limited
EU · EU licence (European Commission)

Deutetrabenazine (Austedo)

Treatment of moderate to severe tardive dyskinesia in adults.

CHMP opinion 5 Nov 2025 → EU licence 8 Jan 2026 · Teva GmbH
EU · EU licence (European Commission)

Germanium (68Ge) chloride;gallium (68Ga) chloride (GalenVita)

This radionuclide generator is not intended for direct use in patients. The sterile eluate (gallium (68Ga) chloride solution) from the radionuclide generator GalenVita is indicated for in vitro&nbsp;radiolabelling of various kits for radiopharmaceutical preparation developed and approved for radiolabelling with such eluate, to be used… Show the full indication

This radionuclide generator is not intended for direct use in patients. The sterile eluate (gallium (68Ga) chloride solution) from the radionuclide generator GalenVita is indicated for in vitro&nbsp;radiolabelling of various kits for radiopharmaceutical preparation developed and approved for radiolabelling with such eluate, to be used for positron emission tomography (PET) imaging.

CHMP opinion 13 Nov 2025 → EU licence 8 Jan 2026 · Curium Romania S.R.L.
EU · EU licence (European Commission)

Teduglutide (Teduglutide Viatris)

Teduglutide Viatris is indicated for the treatment of patients 4 months corrected gestational age and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.

Generic
CHMP opinion 13 Nov 2025 → EU licence 8 Jan 2026 · Viatris Limited
EU · EU licence (European Commission)

Teplizumab (Teizeild)

Teizeild is indicated to delay the onset of stage 3 type 1 diabetes (T1D) in adult and paediatric patients 8 years of age and older with stage 2 T1D.

PRIME
CHMP opinion 13 Nov 2025 → EU licence 8 Jan 2026 · Sanofi Winthrop Industrie

December 2025

US · FDA approval, new medicine

Narsoplimab-wuug (Yartemlea)

To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy

Approved 23 Dec 2025
EU · EU licence (European Commission)

Rilzabrutinib (Wayrilz)

Wayrilz is indicated for the treatment of immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (see section 5.1)

Orphan
CHMP opinion 16 Oct 2025 → EU licence 22 Dec 2025 · Sanofi B.V.
US · FDA approval, new medicine

Lerodalcibep-liga (Lerochol)

To reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise

Approved 12 Dec 2025
EU · CHMP positive opinion: new indication

Voriconazole (Vfend)

New indication (Candidiasis, Mycoses, Aspergillosis). The wording is on the EMA page.

CHMP opinion 11 Dec 2025 · Pfizer Europe MA EEIG

November 2025

EU · EU licence (European Commission)

Nipocalimab (Imaavy)

Imaavy is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult and adolescent patients aged 12 years of age and older who are anti‑acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

CHMP opinion 3 Nov 2025 → EU licence 28 Nov 2025 · Janssen Cilag International NV
EU · EU licence (European Commission)

Insulin icodec;semaglutide (Kyinsu)

Kyinsu is indicated for the treatment of adults with type 2 diabetes mellitus insufficiently controlled on basal insulin or glucagon-like peptide 1 (GLP-1) receptor agonists as an adjunct to diet and exercise in addition to oral antidiabetic medicinal products. For study results with respect to combinations, effects on glycaemic control,… Show the full indication

Kyinsu is indicated for the treatment of adults with type 2 diabetes mellitus insufficiently controlled on basal insulin or glucagon-like peptide 1 (GLP-1) receptor agonists as an adjunct to diet and exercise in addition to oral antidiabetic medicinal products. For study results with respect to combinations, effects on glycaemic control, and the populations studied, see sections 4.4, 4.5 and 5.1.

CHMP opinion 18 Sept 2025 → EU licence 24 Nov 2025 · Novo Nordisk A/S
EU · EU licence (European Commission)

Rivaroxaban (Svariya (previously Rivaroxaban Koanaa))

Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients). Prevention of atherothrombotic events Adults… Show the full indication

Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients). Prevention of atherothrombotic events Adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.&nbsp; Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)&nbsp; Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. Adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.&nbsp; Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).&nbsp; Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. Svariya films should not be prescribed for patients with body weight less than 30 kg.

Generic
CHMP opinion 18 Sept 2025 → EU licence 21 Nov 2025 · PGF Pharma International d.o.o.
US · FDA approval, new medicine

Sevabertinib (Hyrnuo)

To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy

Approved 19 Nov 2025
EU · EU licence (European Commission)

Brensocatib (Brinsupri)

Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.

PRIME
CHMP opinion 16 Oct 2025 → EU licence 18 Nov 2025 · Insmed Netherlands B.V.
EU · EU licence (European Commission)

Vysribli (Vysribli (previously Denosumab Intas))

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women denosumab significantly reduces the risk of vertebral, non-vertebral and hip fractures. Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures (see section 5.1).… Show the full indication

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women denosumab significantly reduces the risk of vertebral, non-vertebral and hip fractures. Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures (see section 5.1). In men with prostate cancer receiving hormone ablation, denosumab significantly reduces the risk of vertebral fractures. Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture (see section 5.1).

Biosimilar
CHMP opinion 18 Sept 2025 → EU licence 17 Nov 2025 · Intas Third Party Sales 2005 S.L.
EU · EU licence (European Commission)

Denosumab (Degevma)

Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

Biosimilar
CHMP opinion 18 Sept 2025 → EU licence 17 Nov 2025 · Teva GmbH
EU · EU licence (European Commission)

Denosumab (Xbonzy)

Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

Biosimilar
CHMP opinion 18 Sept 2025 → EU licence 17 Nov 2025 · Reddy Holding GmbH
EU · EU licence (European Commission)

Denosumab (Kefdensis)

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Kefdensis significantly reduces the risk of vertebral, non-vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures&nbsp;(see section… Show the full indication

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Kefdensis significantly reduces the risk of vertebral, non-vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures&nbsp;(see section 5.1). In men with prostate cancer receiving hormone ablation, Kefdensis significantly reduces the risk of vertebral fractures.Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture (see section 5.1).

Biosimilar
CHMP opinion 18 Sept 2025 → EU licence 17 Nov 2025 · Stada Arzneimittel AG
EU · EU licence (European Commission)

Denosumab (Acvybra)

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Acvybra significantly reduces the risk of vertebral, non-vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate… Show the full indication

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Acvybra significantly reduces the risk of vertebral, non-vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Acvybra significantly reduces the risk of vertebral fractures.Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.

Biosimilar
CHMP opinion 18 Sept 2025 → EU licence 17 Nov 2025 · Reddy Holding GmbH
EU · EU licence (European Commission)

Denosumab (Ponlimsi)

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Ponlimsi significantly reduces the risk of vertebral, non-vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate… Show the full indication

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Ponlimsi significantly reduces the risk of vertebral, non-vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Ponlimsi significantly reduces the risk of vertebral fractures.Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.

Biosimilar
CHMP opinion 18 Sept 2025 → EU licence 17 Nov 2025 · Teva GmbH
EU · EU licence (European Commission)

Denosumab (Zvogra)

Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1). Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely… Show the full indication

Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1). Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

Biosimilar
CHMP opinion 18 Sept 2025 → EU licence 17 Nov 2025 · Stada Arzneimittel AG
EU · EU licence (European Commission)

Golimumab (Gobivaz)

Rheumatoid arthritis (RA) Gobivaz, in combination with methotrexate (MTX), is indicated for: the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid… Show the full indication

Rheumatoid arthritis (RA) Gobivaz, in combination with methotrexate (MTX), is indicated for: the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX. Golimumab, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis (pJIA) Gobivaz in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX. Psoriatic arthritis (PsA) Gobivaz, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.&nbsp;Golimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. Axial spondyloarthritis Ankylosing spondylitis (AS) Gobivaz is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Non-radiographic axial spondyloarthritis (nr-Axial SpA) Gobivaz is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). Ulcerative colitis (UC) Gobivaz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. Paediatric ulcerative colitis (pUC) Gobivaz is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients 2 years of age and older with a body weight of at least 15 kg, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

Biosimilar
CHMP opinion 18 Sept 2025 → EU licence 17 Nov 2025 · Advanz Pharma Limited
EU · EU licence (European Commission)

Ustekinumab (Usgena)

Crohn’s Disease Usgena is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist. Ulcerative colitis Usgena is indicated for the treatment of adult patients with… Show the full indication

Crohn’s Disease Usgena is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist. Ulcerative colitis Usgena is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic. Plaque psoriasis Usgena is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A) (see section 5.1). Paediatric plaque psoriasis Usgena is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies (see section 5.1). Psoriatic arthritis (PsA) Usgena, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate (see section 5.1).

Biosimilar
CHMP opinion 18 Sept 2025 → EU licence 17 Nov 2025 · Stada Arzneimittel AG
EU · CHMP positive opinion: new indication

Eravacycline (Xerava)

New indication (Infection, Bacterial Infections). The wording is on the EMA page.

CHMP opinion 13 Nov 2025 · PAION Pharma GmbH
US · FDA approval, new medicine

Ziftomenib (Komzifti)

To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options

Approved 13 Nov 2025
US · FDA approval, new medicine

Doxecitine and doxribtimine (Kygevvi)

To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger

Approved 3 Nov 2025

October 2025

EU · EU licence (European Commission)

Clascoterone (Winlevi)

Adults&nbsp;Winlevi is indicated for the treatment of acne vulgaris. Adolescents (from 12 to &lt;&nbsp;18&nbsp;years of age)&nbsp;Winlevi is indicated for the treatment of facial acne vulgaris.

CHMP opinion 25 Aug 2025 → EU licence 17 Oct 2025 · Cassiopea S.p.A.

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.